Amgen Q2 Beat, Raised Guidance, and FDA Talks on TAVNEOS Drive Optimism
AMGN sits 52% above its 52-week low of $269.77.
Summary
Amgen's Q2 revenue hit $10.1B, beating estimates, and full-year sales guidance was raised to $38.2–39.4B. Oncology sales surged 18% to ~$2B, with Imdelltra contributing $288M and showing a survival benefit. The company is actively engaging with the FDA on TAVNEOS, having submitted a hearing request and supporting materials. TD Cowen raised its price target to $452, reflecting confidence. A new licensing deal for Kaléo's auto-injector tech broadens Amgen's device portfolio. This follows the Q2 beat reported on August 4 and adds fresh details on pipeline progress and analyst sentiment.
At the time of this announcement, AMGN was trading at $410.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $222.2B. The 52-week trading range was $269.77 to $418.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.